As a member of the Netherlands Society of Cardiology, you are automatically a member of the European Society of Cardiology and the ESC Community. Netherlands Heart Journal is the journal of the ...

Hypertension is the most important modifiable risk factor for all-cause and cardiovascular disease morbidity and mortality. In a departure from the previous guidelines, the 2024 ESC Guidelines on the ...

Take the opportunity to participate in hands-on workshops, explore live heart dissections, experience the popular Simulation Village, and engage with pioneering research through our Late-Breaking ...

Catecholaminergic polymorphic ventricular tachycardia (CPVT) remains one of the most challenging inherited arrhythmia syndromes in contemporary cardiology. Although uncommon, it is associated with a ...

Brussels, 3 December 2024 - Today (3 December), the EU-27 Ministers of Health unanimously adopted the Council Conclusions on the Improvement of Cardiovascular Health in the EU [1], marking a strong ...

The European Society of Cardiology (ESC) is deeply saddened by the passing of Professor Eugene Braunwald, one of the most influential figures in the history of cardiovascular medicine, who died on 22 ...

Our guidelines deliver updated, evidence-based recommendations for managing supraventricular tachycardias – covering drug therapy, ablation, and coexisting conditions.

Taking more steps, even below the recommended daily target of 10,000 steps, and walking faster, significantly lowers the risk of major problems of the heart and blood vessels in people with high blood ...

Peripheral arterial and aortic diseases are highly prevalent and significantly increase cardiovascular mortality and morbidity. The impact and prevalence of these diseases are constantly increasing.

Firstly, Professor Gilles Barone-Rochette (University Hospital of Grenoble - La Tronche, France) presented results from the EVAOLD trial comparing stress imaging-guided selective invasive management ...

Discover the results from ASPIRED, DANISH-CRT, SyncAV PMT, Syncope-Stopper and HIS Alternative II, presented on Monday, 31 August 2026. To start, Professor Matthew Reed (The Usher Institute - ...

Professor Gerald Watts (University of Western Australia - Perth, Australia) presented results from two trials with the APOC3-targeting RNA interference agent, plozasiran, in patients with severe ...